Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2018’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)

– The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects

– The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Cellmid Ltd

CFM Pharma Holding BV

Cypralis Ltd

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

G1 Therapeutics Inc

Kringle Pharma Inc

Mitotech SA

Quark Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Silver Creek Pharmaceuticals Inc

Spherium Biomed SL

STATegics Inc

Stealth BioTherapeutics Inc

Torrent Pharmaceuticals Ltd

Xigen SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 7

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 24

A1M Pharma AB 24

Alloksys Life Sciences BV 24

Am-Pharma BV 24

Angion Biomedica Corp 25

Arch Biopartners Inc 25

Cellmid Ltd 26

CFM Pharma Holding BV 26

Cypralis Ltd 27

DURECT Corp 27

Evotec AG 27

Exponential Biotherapies Inc 28

G1 Therapeutics Inc 28

Kringle Pharma Inc 29

Mitotech SA 29

Quark Pharmaceuticals Inc 30

SBI Pharmaceuticals Co Ltd 30

Silver Creek Pharmaceuticals Inc 31

Spherium Biomed SL 31

STATegics Inc 31

Stealth BioTherapeutics Inc 32

Torrent Pharmaceuticals Ltd 32

Xigen SA 33

Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles 34

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 34

ANG-4102 - Drug Profile 36

BB-3 - Drug Profile 37

brimapitide - Drug Profile 41

CAB-101 - Drug Profile 47

CC-4066 - Drug Profile 49

cilastatin - Drug Profile 50

Drug for Kidney Diseases - Drug Profile 51

DUR-928 - Drug Profile 52

EA-230 - Drug Profile 57

elamipretide - Drug Profile 59

G-1T100182 - Drug Profile 68

IL-233 - Drug Profile 69

iron sucrose + Sn protoporphyrin - Drug Profile 70

K-1052 - Drug Profile 71

KP-100IT - Drug Profile 72

Metablok - Drug Profile 74

MG-53 - Drug Profile 75

NOXD-21 - Drug Profile 77

NYK-1341 - Drug Profile 78

Plastomitin - Drug Profile 79

QPI-1002 - Drug Profile 80

R-190 - Drug Profile 84

Recombinant Alkaline Phosphatase Enzyme Replacement for Acute Kidney Injury - Drug Profile 85

Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile 86

Recombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment and Type 2 Diabetes - Drug Profile 90

Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile 92

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 93

RLS-003 - Drug Profile 94

RMC-035 - Drug Profile 95

SGF-1 - Drug Profile 99

Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 100

Small Molecule to Inhibit PADI4 for Acute Kidney Injury, Hepatic and Pancreatic Injuries - Drug Profile 101

STSE-15 - Drug Profile 102

SUL-138 - Drug Profile 104

TRC-160334 - Drug Profile 105

TTX-332 - Drug Profile 106

Vanadis-03 - Drug Profile 107

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 108

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 110

Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 111

Featured News & Press Releases 111

Appendix 121

Methodology 121

Coverage 121

Secondary Research 121

Primary Research 121

Expert Panel Validation 121

Contact Us 121

Disclaimer 122

List of Tables

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by A1M Pharma AB, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Alloksys Life Sciences BV, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Am-Pharma BV, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Angion Biomedica Corp, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Arch Biopartners Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Cellmid Ltd, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by CFM Pharma Holding BV, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Cypralis Ltd, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by DURECT Corp, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Evotec AG, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Exponential Biotherapies Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by G1 Therapeutics Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Kringle Pharma Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitotech SA, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Quark Pharmaceuticals Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by SBI Pharmaceuticals Co Ltd, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Silver Creek Pharmaceuticals Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Spherium Biomed SL, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by STATegics Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Stealth BioTherapeutics Inc, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Torrent Pharmaceuticals Ltd, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Xigen SA, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, H1 2018 (Contd..1), H1 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports